The need to increase value and productivity throughout the development process has never been more critical. R&D expenditure continued to drop in 2010 to an estimated three-year low of $68 billion, and drug success rates continue to show the declining trends of the past decade, according to the 2011 Pharmaceutical R&D Factbook compiled by CMR International. Additionally, the number of drugs entering Phase I trials fell 47%.
As a result, experts say the bar has been raised for preclinical studies because researchers now know much more about the mechanisms of disease.
Jennifer Brice. Life Sciences Global Program Manager, Frost & Sullivan, which provides research and best-practice models to drive the generation, evaluation, and implementation of growth strategies. For more information, visit frost.com.
Christine Copeman. Scientific Director, Charles River, which helps accelerate drug discovery and development by providing research models and preclinical and clinical support services. For more information, visit criver.com and crivereureka.com.
Christina Fleming, Ph.d. Executive VP of Scientific and Medical Affairs, Advanced Clinical, a provider of clinical research solutions. For more information, visit advancedclinical.com.
Ken Kramer, Ph.d. Senior VP and Medical Director, Alpha & Omega Worldwide, part of The Core Nation, a family of healthcare marketing and medical communications companies that offers strategic, branding, and creative consulting services. For more information, visit thecorenation.com.
Chris Parker. VP and Chief Commercial Officer, Cellular Dynamics International, a developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering, and organ regeneration. For more information, visit cellulardynamics.com.
Pamela Shaver-Walker. Director, Global Reporting Services, Charles River, which helps accelerate drug discovery and development by providing research models and preclinical and clinical support services. For more information, visit criver.com or crivereureka.com.
Philip Toleikis, Ph.D. President and CEO, Sernova Corp., a medical device company benefiting patients with chronic metabolic, neurological, and hematological diseases. For information, visit sernova.com.